10397-13-4

Basic information

• Product Name: 4-(4,6-Dichloropyrimidin-2-yl)morpholine
• Synonyms: 4-(4,6-Dichloropyrimidin-2-yl)morpholine;4-(4,6-Dichloro-2-pyriMidyl)Morpholine;4,6-dichloro-2-MorpholinopyriMidine;4-(4,6-Dichloro-2-pyriMidinyl)Morpholine, 97%;2-(4-Morpholino)-4,6-dichloropyrimidine;2-Morpholine-4,6-dichloropyriMidine;2-Morpholino-4,6-dichloropyrimidine
• CAS NO: 10397-13-4
• Molecular Formula: C₈H₉Cl₂N₃O
• Molecular Weight: 234.08
• Mol File: 10397-13-4.mol
• Article Data: 31

Chemical Properties

• Melting Point: 139.0 to 143.0 °C
• Boiling Point: 392.909 °C at 760 mmHg
• Flash Point: 191.425 °C
• Appearance: White or off-white crystal powder
• Density: 1.435 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.577
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: soluble in Toluene
• PKA: -1.07±0.50(Predicted)
• CAS DataBase Reference: 4-(4,6-Dichloropyrimidin-2-yl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4,6-Dichloropyrimidin-2-yl)morpholine(10397-13-4)
• EPA Substance Registry System: 4-(4,6-Dichloropyrimidin-2-yl)morpholine(10397-13-4)

Safety Data

• Hazardous Substances Data: 10397-13-4(Hazardous Substances Data)

Usage

General Description

4-(4,6-Dichloropyrimidin-2-yl)morpholine is a chemical compound with the molecular formula C8H10Cl2N2O. It is a heterocyclic organic compound that contains a morpholine ring and a pyrimidine ring with two chlorine atoms attached to the pyrimidine ring. 4-(4,6-Dichloropyrimidin-2-yl)morpholine is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It has potential applications in the development of fungicides, herbicides, and pharmaceutical drugs. Additionally, 4-(4,6-Dichloropyrimidin-2-yl)morpholine may also be used as a building block in the synthesis of other complex organic compounds due to its versatile reactivity and functional groups.

InChI:InChI=1/C8H9Cl2N3O/c9-6-5-7(10)12-8(11-6)13-1-3-14-4-2-13/h5H,1-4H2

Upstream product

• 110-91-8 morpholine 
• 3764-01-0 2,4,6-trichloropyrimidine 
• 17238-66-3 morpholine-4-carboxamidine 
• 5414-19-7 1,1'-oxybis(2-bromo-ethane) 
• 56-05-3 2-Amino-4,6-dichloropyrimidine 
• 157415-17-3 Morpholine-4-carboxamidine; hydrobromide 
• 24193-00-8 2-(morpholin-4-yl)pyrimidine-4,6-diol 
• 50596-83-3 2-morpholin-4-yl-1H-pyrimidine-4,6-dione 

Downstream Products

• 544693-01-8 4-(6-chloro-2-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine 
• 887402-10-0 6-[2-(pyridin-2-yl)-ethoxy]-2-chloro-4-(morpholin-4-yl)-pyrimidine 
• 887402-09-7 4-[2-(pyridin-2-yl)-ethoxy]-6-chloro-2-(morpholin-4-yl)-pyrimidine 
• 944401-94-9 N-(6-chloro-2-morpholinopyrimidin-4-yl)-4-phenylthiazol-2-amine 
• 1013402-34-0 N-[2-[(6-chloro-2-morpholin-4-yl-pyrimidin-4-yl)amino]phenyl]-2,2,2-trifluoro-acetamide 

Relevant articles and documents

Regioselective 2-Amination of Polychloropyrimidines

The regioselective amination of substituted di- and trichloropyrimidines affording the 2-substituted products is reported. While aryl- and heteroarylamines require the use of a dialkylbiarylphosphine-derived palladium catalyst for high efficiency, more nucleophilic dialkylamines produce 2-aminopyrimidines under noncatalyzed SNAr conditions. The key is the use of 5-trimethylsilyl-2,4-dichloropyrimidine as a surrogate for the parent dichloropyrimidine. For more challenging cases, the 2-chloro-4-thiomethoxy analogues were prepared and exclusively afford the desired 2-aminated-4-thiomethoxypyrimidine products.

Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy

Concomitant inhibition of PARP and PI3K pathways has been recognized as a promising strategy for cancer therapy, which may expand the clinical utility of PARP inhibitors. Herein, we report the discovery of dual PARP/PI3K inhibitors that merge the pharmaco

PARP-1 and PI3K double-target inhibitor containing benzofuran

The invention relates to the field of medicinal chemistry, in particular to a PARP-1 and PI3K double-target inhibitor containing a benzofuran structure (I) (the formula I is shown in the description),a preparation method and a medicine composition containing thereof. Proved by a pharmacodynamic test, the PARP-1 and PI3K double-target inhibitor has the anti-tumor effect.

PI3K INHIBITOR, AND PHARMACEUTICALLY ACCEPTABLE SALT, POLYCRYSTALLINE FORM, AND APPLICATION THEREOF

The present invention relates to a PI3K inhibitor, and a pharmaceutically acceptable salt, polycrystalline form, and application thereof. The invention specifically provides a polycrystalline form of 4-chloro-5-(6-(1-(methylsulfonyl)cyclopropyl)-2-morpholinopyrimidin-4-yl)pyridin-2-amine, a pharmaceutically acceptable salt thereof, or a polycrystalline form of the salt. The invention further discloses a pharmaceutical composition comprising the inhibitor and an application of the pharmaceutical composition.